Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
36,681,359
-
Shares change
-
+1,182,755
-
Total reported value, excl. options
-
$4,391,736,256
-
Value change
-
+$169,794,588
-
Put/Call ratio
-
84%
-
Number of buys
-
102
-
Number of sells
-
-71
-
Price
-
$119.75
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q3 2017
223 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q3 2017.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36,681,359 shares
of 49,633,071 outstanding shares and own 74% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (5,256,567 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,550,000 shares), VANGUARD GROUP INC (2,549,228 shares), ORBIMED ADVISORS LLC (2,425,735 shares), FMR LLC (2,113,970 shares), JANUS HENDERSON GROUP PLC (1,890,901 shares), BlackRock Inc. (1,814,643 shares), Partner Fund Management, L.P. (1,369,579 shares), STATE STREET CORP (1,287,329 shares), and CITADEL ADVISORS LLC (1,046,080 shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.